1. Home
  2. SRAD vs GKOS Comparison

SRAD vs GKOS Comparison

Compare SRAD & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sportradar Group AG

SRAD

Sportradar Group AG

HOLD

Current Price

$12.49

Market Cap

5.0B

Sector

Technology

ML Signal

HOLD

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$143.44

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SRAD
GKOS
Founded
2001
1998
Country
Switzerland
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Medical/Dental Instruments
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.0B
6.0B
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
SRAD
GKOS
Price
$12.49
$143.44
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
16
12
Target Price
$24.31
$126.92
AVG Volume (30 Days)
5.5M
688.6K
Earning Date
04-28-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$507,442,000.00
Revenue This Year
$24.03
$23.32
Revenue Next Year
$14.81
$27.43
P/E Ratio
$49.48
N/A
Revenue Growth
N/A
32.33
52 Week Low
$11.66
$73.16
52 Week High
$32.22
$146.75

Technical Indicators

Market Signals
Indicator
SRAD
GKOS
Relative Strength Index (RSI) 36.06 69.27
Support Level $11.66 $80.14
Resistance Level $14.44 $146.75
Average True Range (ATR) 0.82 6.00
MACD 0.06 0.59
Stochastic Oscillator 29.68 90.19

Price Performance

Historical Comparison
SRAD
GKOS

About SRAD Sportradar Group AG

Sportradar Group AG is a technology platform enabling next-generation engagement in sports, and a provider of B2B solutions to the sports betting industry. It generates revenue through two primary sources: subscription-based revenue and revenue sharing. Geographically, it operates in North America, Africa, AsiaPac & Middle East, Europe, and LATAM & Caribbean.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: